Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Bill Cavanagh
Institution:
Aldeyra Therapeutics, Inc. (United States)
Observed institutions:
Virginia Eye Consultants,
Aldeyra Therapeutics, Inc. (United States)
ORCID:
0000-0002-3709-0156
Observed ORCID:
0000-0002-3709-0156
OpenAlex ID:
A5089059766
Clinically Relevant Activity of the Novel RASP Inhibitor Reproxalap in Allergic Conjunctivitis: The Phase 3 ALLEVIATE Trial
2021
·
David Clark
, Bill Cavanagh
, et al.
·
American Journal of Ophthalmology
·
38
Reproxalap Activity and Estimation of Clinically Relevant Thresholds for Ocular Itching and Redness in a Randomized Allergic Conjunctivitis Field Trial
2022
·
Bill Cavanagh
, Paul J. Gomes
, et al.
·
Ophthalmology and Therapy
·
13
PDF
A Post-Acute Ocular Tolerability Comparison of Topical Reproxalap 0.25% and Lifitegrast 5% in Patients with Dry Eye Disease
2021
·
David McMullin
, David Clark
, et al.
·
Clinical ophthalmology
·
13
PDF
Phase 3 Randomized Clinical Trial Evaluating the Safety of Reproxalap in Patients With Dry Eye Disease
2026
·
Nathan M. Radcliffe
, John Sheppard
, et al.
·
Ophthalmology and Therapy
·
5
PDF
Effect of Reproxalap Treatment on Dry Eye Disease Symptoms: Analysis of Pooled Data From Two Randomized, Vehicle-Controlled, 12-Week Clinical Trials
2026
·
John D. Sheppard
, Kelly Nichols
, et al.
·
Ophthalmology and Therapy
PDF
Show more works
View as search
Works count:
5
Citation count:
69
H-index:
4
I10-index:
3
Year
Topic
Type